Bath Ankylosing Spondylitis Functional Index (BASFI)
Bath Ankylosing Spondylitis Functional Index · Also known as: BASFI, BAS-FI
The BASFI is a patient-reported outcome measure of functional disability in ankylosing spondylitis (AS), assessing physical limitations in 10 common daily activities. Introduced by Calin et al. in 1994, BASFI measures the impact of AS on quality of life and functional capacity, complementing BASDAI (disease activity). While BASDAI reflects inflammatory burden, BASFI reflects the consequences of inflammation and spinal damage on a patient's ability to perform daily tasks. BASFI is used alongside BASDAI in AS management to capture both disease activity and its functional impact.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
BASFI is a complementary outcome measure used alongside BASDAI in AS management. Use at baseline to establish functional capacity, then at regular intervals (every 3–6 months during treatment) to track functional impact and progression. BASFI is particularly useful for: (1) assessing cumulative functional impact of AS, especially in long-standing disease with spinal fusion; (2) identifying patients with substantial disability despite low BASDAI (activity-independent functional loss); (3) evaluating long-term benefit of therapy beyond disease activity reduction; (4) predicting work disability and need for social support; (5) monitoring response to rehabilitation and physical therapy. BASFI is validated for adults with established AS; not validated for early disease, juvenile-onset AS, or non-spondyloarthropathy conditions.
Strengths & limitations
- Patient-centred; directly measures lived functional experience rather than biomarkers or clinician assessment.
- Practical and quick; 10 items, self-administered in 2–3 minutes; suitable for routine clinical practice.
- Specific to AS; items selected to reflect functional challenges unique to spinal disease (bending, rising from low surfaces, stair climbing).
- Stable over time; BASFI reflects accumulated spinal damage and is less volatile than BASDAI; useful for long-term tracking.
- Associated with spinal radiographic damage and disability; elevated BASFI predicts work loss and disability benefits.
- Responsive to rehabilitation and physical therapy; shows improvement with structured exercise programs independent of medication.
- Complementary to BASDAI; captures functional impact distinct from disease activity, enabling comprehensive outcome assessment.
- Patient self-report; accuracy influenced by psychological distress, catastrophising, depression, or concurrent non-inflammatory pain conditions.
- Does not distinguish inflammatory functional limitation (reversible with treatment) from structural spinal damage (largely irreversible); high BASFI in late-stage spinal fusion may not improve with medication.
- Limited sensitivity to change in short term (weeks to months); BASFI is more stable than BASDAI and better reflects long-term impact.
- Does not capture upper extremity or hip function, which may be substantially impaired in AS; limited to spinal and ambulation-dependent activities.
- Ceiling and floor effects possible; severe disease may be difficult to differentiate, and mild disease may not discriminate minor functional changes.
- Does not include objective measurements (e.g., range of motion, timed tests); subjective ratings may not align with physical examination findings.
- BASFI is independent of disease activity; low BASDAI with high BASFI reflects established damage not amenable to further medication optimization.
Frequently asked
What is the difference between BASFI and BASDAI?
BASDAI measures disease activity (inflammation, pain, stiffness); BASFI measures functional impact (disability, limitation in daily activities). A patient may have low BASDAI (controlled disease) but high BASFI (substantial limitation from previous damage), or vice versa. Both should be monitored; therapy aims to reduce BASDAI and prevent BASFI worsening.
What does a BASFI of 7 mean?
A BASFI of 7 indicates substantial functional limitation—difficulty with most activities (stairs, bending, dressing). This reflects significant cumulative impact of AS, either from active disease, structural damage, or both. Work capacity may be significantly impaired. Investigate with BASDAI and imaging to determine if limitation is inflammation-driven (treatable) or damage-driven (structural).
Can BASFI improve with medication alone?
BASFI may improve modestly with anti-TNF therapy if inflammation-driven, but improvement is typically smaller than BASDAI improvement. Structural spinal damage (ankylosis, vertebral fracture) does not reverse with medication; physical rehabilitation, exercise, and occupational therapy are often more effective for functional improvement in late-stage disease.
What if my BASFI is high but my BASDAI is low?
High BASFI with low BASDAI suggests functional limitation from structural spinal damage (ankylosis, fusion, deformity) rather than active inflammation. This is common in long-standing AS. Consider: (1) structural imaging (X-ray, CT, MRI) to confirm damage; (2) physical examination for spinal mobility and kyphosis; (3) referral to physical therapy and rehabilitation; (4) investigation of other causes (deconditioning, depression, pain amplification). Increasing anti-TNF dose is unlikely to improve BASFI in this scenario.
How often should BASFI be assessed?
BASFI is less volatile than BASDAI and reflects long-term functional impact. Assess every 6–12 months during stable maintenance therapy. More frequent assessment (every 3 months) may be useful during rehabilitation to track therapy-driven improvement. Very frequent assessment (monthly) is not recommended as BASFI does not change rapidly.
Is BASFI used in remission criteria for AS?
No. ASAS remission criteria focus on BASDAI, CRP/ESR, and inflammation markers; BASFI is not part of remission definition. BASFI reflects functional impact (long-term consequence) rather than activity state. A patient can be in disease remission (BASDAI <4, CRP normal) but have high BASFI from previous damage.
What is BASFI 50?
BASFI 50 refers to a ≥50% reduction in BASFI score from baseline. This is a secondary efficacy endpoint in some AS trials. For example, if baseline BASFI = 8, then BASFI 50 = achieving BASFI ≤4. BASFI 50 responses are slower to develop than BASDAI 50, reflecting the time required for functional reconditioning and rehabilitation.
Can BASFI be used for non-AS spondyloarthropathies?
BASFI is validated for ankylosing spondylitis and non-radiographic axial spondyloarthropathy. For peripheral-predominant psoriatic or reactive arthritis, BASFI may not be appropriate; disease-specific functional measures should be used. BASFI assumes axial/spinal disease predominance.
Sources
- Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. 1994;21(12):2281-2285. link ↗
How to cite this page
ScholarGate. (2026, June 3). Bath Ankylosing Spondylitis Functional Index. ScholarGate. https://scholargate.app/en/rheumatology/basfi
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Bath Ankylosing Spondylitis Disease Activity IndexRheumatology↔ compare
- Disease Activity Score 28Rheumatology↔ compare
- Routine Assessment of Patient Index Data 3Rheumatology↔ compare
- Systemic Lupus Erythematosus Disease Activity IndexRheumatology↔ compare